Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Pipeline Review, H2 2017

  • ID: 4429844
  • Report
  • 118 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc
  • BerGenBio ASA
  • Celldex Therapeutics Inc
  • Daiichi Sankyo Co Ltd
  • Exelixis Inc
  • Ignyta Inc
  • MORE
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Pipeline Review, H2 2017

Summary

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Tyrosine Protein Kinase Receptor UFO - Pipeline Review, H2 2017, outlays comprehensive information on the Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Tyrosine-protein kinase receptor UFO is an enzyme encoded by the AXL gene. It plays a role in various processes such as endothelial cell survival during acidification by preventing apoptosis, optimal cytokine signaling during human natural killer cell development, hepatic regeneration, gonadotropin-releasing hormone neuron survival and migration, platelet activation, or regulation of thrombotic responses. It plays also an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 4, 11 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Cardiovascular which include indications Non-Small Cell Lung Cancer, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Refractory Acute Myeloid Leukemia, Gastric Cancer, Ovarian Cancer, Relapsed Acute Myeloid Leukemia, Bladder Cancer, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Lung Adenocarcinoma, Lung Cancer, Metastatic Colorectal Cancer, Pancreatic Cancer, Soft Tissue Sarcoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Bile Duct Cancer (Cholangiocarcinoma), Bone Metastasis, Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Ewing Sarcoma, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor (GIST), Head And Neck Cancer, Hematological Tumor, Kidney Cancer (Renal Cell Cancer), Liposarcoma, Liver Cancer, Melanoma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Prostate Cancer, Metastatic Renal Cell Carcinoma, Myelodysplastic Syndrome, Neuroendocrine Tumors, Non-Rhabdomyosarcoma, Ocular Melanoma, Osteosarcoma, Pancreatic Ductal Adenocarcinoma, Papillary Renal Cell Carcinoma, Peritoneal Cancer, Pheochromocytoma, Recurrent Glioblastoma Multiforme (GBM), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Rhabdomyosarcoma, Thrombosis, Thyroid Cancer, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ureter Cancer, Urethral Cancer, Uterine Cancer and Wilms' Tumor (Nephroblastoma).

Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)
  • The report reviews Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc
  • BerGenBio ASA
  • Celldex Therapeutics Inc
  • Daiichi Sankyo Co Ltd
  • Exelixis Inc
  • Ignyta Inc
  • MORE
Introduction

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Overview

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Companies Involved in Therapeutics Development

Astellas Pharma Inc

BerGenBio ASA

Betta Pharmaceuticals Co Ltd

Celldex Therapeutics Inc

Daiichi Sankyo Co Ltd

Exelixis Inc

Ignyta Inc

Les Laboratoires Servier SAS

Mirati Therapeutics Inc

Ono Pharmaceutical Co Ltd

Oribase Pharma

Qurient Co Ltd

Rigel Pharmaceuticals Inc

SignalChem Lifesciences Corp

Takeda Pharmaceutical Co Ltd

Tolero Pharmaceuticals Inc

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Drug Profiles

Antibodies to Inhibit AXL, MERTK and TYRO3 for Oncology, Inflammation, Autoimmune Diseases and Infectious Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGB-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGB-149 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGB-324 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGB-601 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BPI-9016 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cabozantinib s-malate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CT-053 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CT-413 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-1205 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Inhibit Axl Tyrosine kinase for Thrombosis and Non-Small Cell Lung Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gilteritinib fumarate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glesatinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HOPE-777 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-7475 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Q-701 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-916562 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RXDX-106 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-49076 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sitravatinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLC-0211 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit AXL for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit AXL, FLT3 and ARK5 for Solid Tumor and Hematological Tumor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TP-0903 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Dormant Products

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Discontinued Products

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Product Development Milestones

Featured News & Press Releases

Nov 08, 2017: Ignyta Announces New Data Highlighting Immune Modulation of RXDX-106 at the Society for Immunotherapy of Cancer Meeting

Nov 01, 2017: Clinical Study with BGB324, BerGenBios Selective First-in-Class AXL Inhibitor, Featured at the 2017 American Society of Hematology Annual Meeting

Oct 19, 2017: BerGenBio Announces Start of Phase II Trial Assessing Selective AXL Inhibitor BGB324 in Combination with KEYTRUDA for Patients with Advanced Breast Cancer

Oct 16, 2017: Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell Carcinoma

Oct 16, 2017: Exelixis’ Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma

Oct 16, 2017: Ipsen announces that phase 3 CELESTIAL trial of cabozantinib meets primary endpoint of overall survival in patients with advanced hepatocellular carcinoma

Oct 12, 2017: Clinical Study with BGB324, BerGenBios Selective First-in-Class AXL Inhibitor, to be Presented at the 9th World Congress of Melanoma

Oct 11, 2017: U.S. FDA Grants Fast Track Designation to Astellas for Development of Gilteritinib in Relapsed or Refractory Acute Myeloid Leukemia

Oct 05, 2017: Tolero Pharma To Provide Update On TP-0903 At 9th International Conference On Leukemia And Hematologic Oncology

Oct 02, 2017: Ignyta Announces New Data Highlighting Immuno-Oncological Efficacy of RXDX-106 at 2017 AACR Tumor Immunology and Immunotherapy Meeting

Sep 28, 2017: BGB324, BerGenBio’s Selective First-in-Class AXL Inhibitor, Featured in Three Clinical Presentations at the 18th World Conference on Lung Cancer

Sep 14, 2017: Mirati Therapeutics Presents Positive Preliminary Data From On-Going Clinical Trials Of Sitravatinib In Non-Small Cell Lung Cancer

Sep 09, 2017: Exelixis and Ipsen Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017

Sep 08, 2017: Ipsen receives validation from European Medicines Agency for the application of a new indication for Cabometyx (cabozantinib) for first-line treatment of advanced renal cell carcinoma in adults

Sep 06, 2017: Exelixis to Co-Host Investor/Media Briefing to Discuss Data Presented at the ESMO 2017 Congress

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Astellas Pharma Inc, H2 2017

Pipeline by BerGenBio ASA, H2 2017

Pipeline by Betta Pharmaceuticals Co Ltd, H2 2017

Pipeline by Celldex Therapeutics Inc, H2 2017

Pipeline by Daiichi Sankyo Co Ltd, H2 2017

Pipeline by Exelixis Inc, H2 2017

Pipeline by Ignyta Inc, H2 2017

Pipeline by Les Laboratoires Servier SAS, H2 2017

Pipeline by Mirati Therapeutics Inc, H2 2017

Pipeline by Ono Pharmaceutical Co Ltd, H2 2017

Pipeline by Oribase Pharma, H2 2017

Pipeline by Qurient Co Ltd, H2 2017

Pipeline by Rigel Pharmaceuticals Inc, H2 2017

Pipeline by SignalChem Lifesciences Corp, H2 2017

Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017

Pipeline by Tolero Pharmaceuticals Inc, H2 2017

Dormant Products, H2 2017

Dormant Products, H2 2017 (Contd..1), H2 2017

Discontinued Products, H2 2017

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Astellas Pharma Inc
  • BerGenBio ASA
  • Betta Pharmaceuticals Co Ltd
  • Celldex Therapeutics Inc
  • Daiichi Sankyo Co Ltd
  • Exelixis Inc
  • Ignyta Inc
  • Les Laboratoires Servier SAS
  • Mirati Therapeutics Inc
  • Ono Pharmaceutical Co Ltd
  • Oribase Pharma
  • Qurient Co Ltd
  • Rigel Pharmaceuticals Inc
  • SignalChem Lifesciences Corp
  • Takeda Pharmaceutical Co Ltd
  • Tolero Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll